These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38837628)

  • 1. CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects.
    Zheng Y; Wang Y; Xiong X; Zhang L; Zhu J; Huang B; Liu X; Liu J; Zhu Z; Yang G; Qu H; Zheng H
    Adv Sci (Weinh); 2024 Aug; 11(29):e2400819. PubMed ID: 38837628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression.
    Nason SR; Kim T; Antipenko JP; Finan B; DiMarchi R; Hunter CS; Habegger KM
    Endocrinology; 2020 Jan; 161(1):. PubMed ID: 31673703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21.
    Kim T; Nason S; Holleman C; Pepin M; Wilson L; Berryhill TF; Wende AR; Steele C; Young ME; Barnes S; Drucker DJ; Finan B; DiMarchi R; Perez-Tilve D; Tschöp M; Habegger KM
    Diabetes; 2018 Sep; 67(9):1773-1782. PubMed ID: 29925501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
    Boland ML; Laker RC; Mather K; Nawrocki A; Oldham S; Boland BB; Lewis H; Conway J; Naylor J; Guionaud S; Feigh M; Veidal SS; Lantier L; McGuinness OP; Grimsby J; Rondinone CM; Jermutus L; Larsen MR; Trevaskis JL; Rhodes CJ
    Nat Metab; 2020 May; 2(5):413-431. PubMed ID: 32478287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon receptor signaling regulates weight loss via central KLB receptor complexes.
    Nason SR; Antipenko J; Presedo N; Cunningham SE; Pierre TH; Kim T; Paul JR; Holleman C; Young ME; Gamble KL; Finan B; DiMarchi R; Hunter CS; Kharitonenkov A; Habegger KM
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33411693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic glucagon action is essential for exercise-induced reversal of mouse fatty liver.
    Berglund ED; Lustig DG; Baheza RA; Hasenour CM; Lee-Young RS; Donahue EP; Lynes SE; Swift LL; Charron MJ; Damon BM; Wasserman DH
    Diabetes; 2011 Nov; 60(11):2720-9. PubMed ID: 21885872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice.
    Galsgaard KD; Elmelund E; Johansen CD; Bomholt AB; Kizilkaya HS; Ceutz F; Hunt JE; Kissow H; Winther-Sørensen M; Sørensen CM; Kruse T; Lau JF; Rosenkilde MM; Ørskov C; Christoffersen C; Holst JJ; Wewer Albrechtsen NJ
    Mol Metab; 2022 Dec; 66():101639. PubMed ID: 36400402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
    Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
    Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon receptor signaling at white adipose tissue does not regulate lipolysis.
    Vasileva A; Marx T; Beaudry JL; Stern JH
    Am J Physiol Endocrinol Metab; 2022 Oct; 323(4):E389-E401. PubMed ID: 36002172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.
    Winther-Sørensen M; Galsgaard KD; Santos A; Trammell SAJ; Sulek K; Kuhre RE; Pedersen J; Andersen DB; Hassing AS; Dall M; Treebak JT; Gillum MP; Torekov SS; Windeløv JA; Hunt JE; Kjeldsen SAS; Jepsen SL; Vasilopoulou CG; Knop FK; Ørskov C; Werge MP; Bisgaard HC; Eriksen PL; Vilstrup H; Gluud LL; Holst JJ; Wewer Albrechtsen NJ
    Mol Metab; 2020 Dec; 42():101080. PubMed ID: 32937194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barley sprout extracts reduce hepatic lipid accumulation in ethanol-fed mice by activating hepatic AMP-activated protein kinase.
    Kim YJ; Hwang SH; Jia Y; Seo WD; Lee SJ
    Food Res Int; 2017 Nov; 101():209-217. PubMed ID: 28941686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation.
    Yoo J; Cho IJ; Jeong IK; Ahn KJ; Chung HY; Hwang YC
    Toxicol Appl Pharmacol; 2018 Dec; 360():18-29. PubMed ID: 30253173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oleuropein attenuates hepatic steatosis induced by high-fat diet in mice.
    Park S; Choi Y; Um SJ; Yoon SK; Park T
    J Hepatol; 2011 May; 54(5):984-93. PubMed ID: 21145829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.
    Longuet C; Robledo AM; Dean ED; Dai C; Ali S; McGuinness I; de Chavez V; Vuguin PM; Charron MJ; Powers AC; Drucker DJ
    Diabetes; 2013 Apr; 62(4):1196-205. PubMed ID: 23160527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice.
    Han S; Akiyama TE; Previs SF; Herath K; Roddy TP; Jensen KK; Guan HP; Murphy BA; McNamara LA; Shen X; Strapps W; Hubbard BK; Pinto S; Li C; Li J
    J Lipid Res; 2013 Oct; 54(10):2615-22. PubMed ID: 23828778
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Shi Y; Pizzini J; Wang H; Das F; Abdul Azees PA; Ghosh Choudhury G; Barnes JL; Zang M; Weintraub ST; Yeh CK; Katz MS; Kamat A
    Am J Physiol Endocrinol Metab; 2021 Jul; 321(1):E90-E104. PubMed ID: 34029162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.